Wednesday, March 29, 2023 Daily Archives

Bicycle and Novartis team to develop Radio-Conjugates

by

The collaboration will see Novartis help to discover, develop, and commercialize Bicycle’s Radio-Conjugates (BCRs). Bicycle Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies based on its bicyclic peptide technology, has signed a deal with Novartis to advance and produce BRCs for numerous oncology targets. Under the terms of the agreement, Bicycle will use its bicyclic peptide technology to discover “Bicycles” to be developed into BRCs. Novartis will be responsible for further advancement, production, and commercialization. “It’s a similar construct…

March 29, 2023

On the defense: Resilience bags $410m US Gov contract

by

The retrospective financing will bolster National Resilience’s US production network and forms part of the US Department of Defense’s Biomanufacturing Strategy. The $410 million long-term funding agreement with the US Department of Defense (DoD), in collaboration with the US International Development Finance Corporation (DFC), aims to support Resilience’s capabilities and strengthen domestic bioproduction. “The loan financing will be used to help expand and modernize the US’s biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids – therapeutic modalities and…

March 29, 2023

Eliminate Noisy Oxygen Measurements in Bioreactors for Good and Control Your Process with Ease!

by

Achieving process consistency is a critical goal in cell culture and fermentation operations. However, one common challenge in these processes is the accumulation of air bubbles on oxygen sensors. This can cause severe signal noise, which in turn can mask the true oxygen level, complicating process control and leading to variability. To avoid this issue, robust aeration control is crucial. You can improve growth, productivity, and product quality by ensuring adequate oxygen supply to cells. However, air bubbles on oxygen…

March 29, 2023

BioNTech heads to Israel to build mRNA vax plant

by

BioNTech has signed a Memorandum of Understanding (MoU) to build a plant in Jerusalem, Israel to manufacture mRNA-based vaccines. The Mayor of Jerusalem, Moshe Lion, told delegates at Mind the Tech Conference in London, UK that BioNTech is “one of the miracles” that helped the world make it through the COVID-19 pandemic after jointly developing BNT162b2 (Comirnaty) with Pfizer, the first messenger RNA (mRNA) COVID-19 vaccine to receive emergency use approval in December 2020. Lion said he wanted  “to begin by…

March 29, 2023